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Background
Whether the treatment of patients with hypertension who are 80 years of age or 
older is beneficial is unclear. It has been suggested that antihypertensive therapy 
may reduce the risk of stroke, despite possibly increasing the risk of death.
Methods
We randomly assigned 3845 patients from Europe, China, Australasia, and Tunisia 
who were 80 years of age or older and had a sustained systolic blood pressure of 
160 mm Hg or more to receive either the diuretic indapamide (sustained release, 1.5 
mg) or matching placebo. The angiotensin-converting–enzyme inhibitor perindopril 
(2 or 4 mg), or matching placebo, was added if necessary to achieve the target blood 
pressure of 150/80 mm Hg. The primary end point was fatal or nonfatal stroke.
Results
The active-treatment group (1933 patients) and the placebo group (1912 patients) 
were well matched (mean age, 83.6 years; mean blood pressure while sitting, 
173.0/90.8 mm Hg); 11.8% had a history of cardiovascular disease. Median follow-up 
was 1.8 years. At 2 years, the mean blood pressure while sitting was 15.0/6.1 mm Hg 
lower in the active-treatment group than in the placebo group. In an intention-to-
treat analysis, active treatment was associated with a 30% reduction in the rate of 
fatal or nonfatal stroke (95% confidence interval [CI], −1 to 51; P = 0.06), a 39% reduc-
tion in the rate of death from stroke (95% CI, 1 to 62; P = 0.05), a 21% reduction in 
the rate of death from any cause (95% CI, 4 to 35; P = 0.02), a 23% reduction in the 
rate of death from cardiovascular causes (95% CI, −1 to 40; P = 0.06), and a 64% re-
duction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse 
events were reported in the active-treatment group (358, vs. 448 in the placebo group; 
P = 0.001).
Conclusions
The results provide evidence that antihypertensive treatment with indapamide (sus-
tained release), with or without perindopril, in persons 80 years of age or older is 
beneficial. (ClinicalTrials.gov number, NCT00122811.)
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Blood-pressure reduction is effec-tive in preventing stroke and other vascu-lar events, including heart failure.1 In the 
past decade, treatment benefits have appeared to 
be broadly consistent among a range of subpopu-
lations and among antihypertensive agents.2 How-
ever, as highlighted by earlier3 and more recent4 
guidelines, evidence that treating patients 80 years 
of age or older is beneficial is inconclusive. Al-
though the risk of stroke increases continuously 
with increasing blood pressures above approxi-
mately 115/75 mm Hg, the association of blood 
pressure and stroke attenuates with increasing 
age.1 Epidemiologic population studies have con-
sistently suggested that blood pressure and the 
risk of death are inversely related among people 
80 years of age or older,5-9 possibly reflecting in-
creased risks of therapy for blood-pressure reduc-
tion or reverse causation due to conditions that 
may be associated with blood-pressure reduction 
(such as cancer, dementia, myocardial infarction, 
and heart failure).
A recent retrospective cohort analysis of pa-
tients 80 years of age or older with hypertension, 
of whom 84.5% were receiving antihypertensive 
medication, reported a shorter survival for those 
with systolic blood pressure levels below 140 
mm Hg, even after adjustment for known predic-
tors of death.10 Randomized controlled trials in-
volving older adults either have excluded those 
80 years of age or older11,12 or have recruited too 
few to show an advantage of treatment.13-16 A 
meta-analysis of results regarding the treatment 
of hypertension specifically in this age group 
suggested that the benefit — a 36% reduction in 
the risk of stroke — might be offset by possible 
adverse effects, given a nearly significant in-
crease, by 14%, in the risk of death from any cause 
(P = 0.05).17 These positive results were not robust, 
since addition of data from just one hypothetical, 
properly designed trial that showed no treatment 
effect would render the results not significant.
The results of the pilot study for the Hyper-
tension in the Very Elderly Trial (HYVET)18 were 
consistent with those from the meta-analysis. 
Both results suggest that treatment for hyperten-
sion was associated with a reduction in stroke but 
also a possible increase in death from any cause, 
such that for each stroke prevented, there was one 
death from a cause other than stroke. In the main 
HYVET study, we aimed to resolve persistent ar-
eas of clinical uncertainty about the relative ben-
efits and risks of antihypertensive treatment in 
patients 80 years of age or older.
Me thods
The detailed protocol for HYVET has been pub-
lished previously.19 HYVET was a randomized, 
double-blind, placebo-controlled trial performed 
in 195 centers in 13 countries in Western and East-
ern Europe, China, Australasia, and North Africa. 
Approval for the trial was obtained from the ap-
propriate authorities and central or local ethics 
committees, as required. All patients gave written 
informed consent, except those who were illiter-
ate, for whom an independent witness signed the 
consent form.
HYVET was funded by grants from the British 
Heart Foundation and the Institut de Recherches 
Internationales Servier. The trial was coordinated 
by staff of the Department of Care of the Elderly, 
Imperial College London. Imperial College Lon-
don required all committee members and inves-
tigators to sign confidentiality agreements. All 
data management was performed by the authors 
who were at Imperial College London. The in-
terim analyses were performed by, and the final 
analysis verified by, an academic author, indepen-
dently of Imperial College London. All the authors 
contributed to the writing of the manuscript and 
the lead authors vouch for the completeness and 
accuracy of the results.
Patients had to be 80 years of age or older 
(confirmed by national documentation) with per-
sistent hypertension (defined as a sustained sys-
tolic blood pressure of 160 mm Hg). Exclusion 
criteria included a contraindication to use of the 
trial medications, accelerated hypertension, sec-
ondary hypertension, hemorrhagic stroke in the 
previous 6 months, heart failure requiring treat-
ment with antihypertensive medication, a serum 
creatinine level greater than 150 μmol per liter 
(1.7 mg per deciliter), a serum potassium level of 
less than 3.5 mmol per liter or more than 5.5 
mmol per liter, gout, a diagnosis of clinical de-
mentia, and a requirement of nursing care.
Patients were instructed to stop all antihyper-
tensive treatment and to take a single placebo 
tablet daily for at least 2 months and to undergo 
two blood-pressure measurements during each of 
two visits, 1 month apart, after having been seated 
for 5 minutes. On the third visit and thereafter, 
the standing blood pressure was taken twice, 
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after the patient had been standing for 2 minutes. 
At the start of the trial, blood pressures were 
recorded with the use of either a mercury sphyg-
momanometer or a validated automated device, 
but by the end of the trial, a validated automated 
device was used in the majority of centers.
If the mean of the four systolic blood-pressure 
measurements taken at the second and third vis-
its (two at each visit) was between 160 and 199 
mm Hg, patients underwent randomization, pro-
vided that all inclusion and exclusion criteria were 
met. Randomization was stratified according to 
age (80 to 89 years and 90 years or older) and 
sex; permuted blocks of 4 and 6 of any 10 pa-
tients were used to ensure roughly equal assign-
ment to each of the two groups within large 
centers. At the start of the trial in 2000, the 
mean diastolic blood pressure while seated had 
to be 90 to 109 mm Hg, but in 2003 a protocol 
amendment relaxed this criterion to be under 
110 mm Hg, allowing for the inclusion of pa-
tients with isolated systolic hypertension. The 
criterion of systolic blood pressure while stand-
ing remained the same throughout the trial, at 
140 mm Hg or more.
After randomization, patients received either 
indapamide (sustained release, 1.5 mg) or match-
ing placebo alone. At each visit (or at the discre-
tion of the investigator), if needed to reach the 
target blood pressure, perindopril (2 mg or 4 mg) 
or matching placebo could be added. The target 
systolic blood pressure was less than 150 mm Hg, 
and the target diastolic blood pressure was less 
than 80 mm Hg. The use of additional antihyper-
tensive agents for more than 3 months resulted 
in withdrawal of the patient from double-blind 
follow-up, with an option to enter open follow-up. 
Patients were also withdrawn from double-blind 
treatment if they had received the maximum 
dose of the study drugs yet had a systolic blood 
pressure while sitting of 220 mm Hg or more or 
if they had a diastolic blood pressure while sitting 
of 110 mm Hg or more on at least two consecu-
tive visits that were 2 or more weeks apart.
Data Collection
Baseline characteristics were recorded during the 
placebo run-in period. After randomization, pa-
tients were seen at least every 3 months during 
the first year and at least every 6 months thereaf-
ter. Investigators were permitted to adjust the dose 
of the trial medication more frequently than at 
each visit, if desired. At the annual visits, infor-
mation was collected on current diseases, medi-
cation, blood pressure, biochemical levels (sodium, 
potassium, urea, creatinine, glucose, uric acid), 
cholesterol levels (total and high-density lipopro-
tein), and hematologic measures (hemoglobin, 
hematocrit), and electrocardiography and an as-
sessment of cognitive function with the use of 
the Mini–Mental State Examination were per-
formed. If the patient was enrolled in an optional 
add-on study, a quality-of-life questionnaire was 
also completed. At the 3-month and 6-month vis-
its, only data on current diseases, medication, and 
blood pressure were collected.
End Points
The primary end point of the trial was any stroke 
(fatal or nonfatal). This end point did not include 
transient ischemic attacks. Secondary end points 
included death from any cause, death from car-
diovascular causes, death from cardiac causes, 
and death from stroke. All events that were pos-
sible end points were reviewed by an independent 
committee, unaware of the group assignment, 
using predefined definitions from the protocol.19 
Events were classified as cardiovascular or non-
cardiovascular. Death from cardiac causes in-
cluded fatal myocardial infarction, fatal heart 
failure, and sudden death. Heart failure was di-
agnosed if the patient had at least one of four 
symptoms (paroxysmal nocturnal dyspnea, dys-
pnea at rest, orthopnea, or symptoms consistent 
with New York Heart Association class III heart 
failure20) and at least two of seven signs (rales or 
crepitations, moderate ankle edema, tachycardia 
[120 or more beats per minute], a third heart 
sound, elevated jugular venous pressure, cardio-
megaly, or radiologic signs characteristic of heart 
failure). If the two signs present were rales and 
ankle edema, a third sign was required.
Data Monitoring
An independent data monitoring committee met 
twice a year throughout the trial to monitor the 
quality of the data and also met at prespecified 
intervals (after every 70 reported stroke events) to 
perform interim analyses. The interim analyses 
of the primary end point were monitored accord-
ing to an O’Brien–Fleming guideline; death from 
any cause was monitored to detect a possible in-
creased risk in the active-treatment group. On 
the basis of the committee’s recommendations, 
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four centers were closed after the first year of the 
trial because of concerns that these centers failed 
to provide complete and accurate data. Specifi-
cally, one center was closed because of a failure 
to identify all the biochemical data in the source 
documents, one because of a failure to obtain 
appropriate regulatory approval, one owing to 
inappropriate drug delivery, and one owing to a 
failure to use validated equipment for measuring 
blood pressure.
Statistical Analysis
HYVET was designed to detect a 35% reduction 
in the rate of any stroke, with a statistical power 
of 90% at the 1% level of significance and assum-
ing an event rate of 40 per 1000 patient-years. We 
calculated that 10,500 patient-years of follow-up 
would be required, with equal numbers of pa-
tients assigned to the active-treatment group and 
the placebo group. The first patient underwent 
randomization in February 2001. After the first 
interim analysis in 2005, the data monitoring 
committee recommended that the trial continue 
with no change to the protocol. At the second 
interim analysis, in July 2007, after 140 strokes 
had been reported (through April 30, 2007; a to-
tal of 7399 patient-years of follow-up), the active-
treatment group showed evidence of a reduction 
in the rate of the primary end point of any stroke 
(relative risk, 0.59; 95% confidence interval [CI], 
0.40 to 0.88; P = 0.009) and, unexpectedly, for 
death from any cause (relative risk, 0.76; 95% CI, 
0.62 to 0.93; P = 0.007). The trial was terminated 
at that point, for ethical reasons. All final visits 
were completed by October 12, 2007. Data and 
events reported before the final visit were includ-
ed in the final analysis.
The primary analysis was performed accord-
ing to the intention-to-treat principle. Data from 
patients were analyzed for the groups to which 
the patients were assigned, regardless of which 
study drugs (or which doses) the patients actu-
ally received and regardless of other protocol ir-
regularities. Patients from closed centers were 
included in the intention-to-treat population and 
contributed person-years and events up to the date 
of closure of the center, after which no further 
information was available.
In the intention-to-treat analysis, patient-years 
were calculated from the date of randomization 
through the date of death or the last available 
visit, irrespective of the type of follow-up (dou-
ble-blind or open). Patients who were withdrawn 
from double-blind follow-up for reasons other 
than withdrawal of consent were followed in an 
open-label fashion, with the same schedule of 
visits. Events that occurred during the open fol-
low-up period were included in the intention-to-
treat analysis. A per-protocol analysis was also 
performed; it excluded data from any patients who 
underwent randomization in error, who were 
stratified incorrectly for either age or sex, or who 
did not receive the correct, assigned study drugs. 
For this analysis, patient-years were calculated 
from the date on which the study drugs were initi-
ated through the time the patient became ineli-
gible to continue with double-blind follow-up, ac-
cording to the protocol19 (i.e., when the patient 
had an event that required withdrawal from dou-
ble-blind treatment).
We compared the means of continuous vari-
ables by using the z-test, proportions by using the 
chi-square test, and incidence rates by using the 
log-rank test. In the log-rank and Cox analyses of 
fatal or nonfatal strokes and death from specific 
causes, death from any cause and death from a 
cause other than the specific cause, respectively, 
were regarded as events for which data were 
censored. Cumulative-incidence curves were es-
timated by means of the Kaplan–Meier method. 
P values less than 0.05 were considered to indi-
cate statistical significance. For patients with more 
than one end point during the follow-up period, 
the time to the first relevant end point was used 
in each analysis. Results for death from fatal or 
nonfatal stroke, death from any cause, and death 
from cardiovascular causes were adjusted for sex, 
age, baseline systolic blood pressure measured 
while the patient was seated, and previous cardio-
vascular disease. The proportional-hazard assump-
tion was verified by plotting the Schoenfeld re-
siduals. All reported P values are two-sided and 
were not adjusted for multiple testing. Data man-
agement and analyses were performed with the 
use of Stata software (version 8.1) (StatCorp) and 
SAS software (version 9.1.3) (SAS Institute).
R esult s
A total of 4761 patients entered the placebo run-in 
phase. Of these, 3845 were randomly assigned to 
one of the two study groups. The reasons for non-
randomization are listed in Figure 1. Patients were 
recruited from Western Europe (86 patients), East-
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3845 Underwent randomization
4761 Patients entered the placebo run-in phase
916 Did not undergo randomization
59 Were in run-in phase when trial was
stopped
12 Were eligible but did not undergo 
randomization before trial was stopped
280 Withdrew consent
461 Did not meet protocol criteria
65 Were at a center that closed
9 Were at a center at which quota had
 been reached
30 Died
1933 Were assigned
to active treatment
1912 Were assigned
to placebo
12 Were withdrawn for the
per-protocol analysis
4 Underwent randomization
in error
6 Did not receive correct
treatment
1 Was randomized to wrong 
stratum
1 Had group-assignment-code
envelope broken at the time of 
randomization
1933 Were included
in the intention-to-
treat analysis
(4149 total patient-yr)
1912 Were included
in the intention-to-
 treat analysis
(3942 total patient-yr)
Event for which data were censored
235 Died
266 Declined to participate
5 Were withdrawn by
investigator
42 Had a protocol withdrawal 
event and no open follow-up
166 Were at centers closed by 
data monitoring committee
171 Had other administrative
reasons
1016 Were alive at end of trial
11 Were lost to follow-up
Event for which data were censored
196 Died
282 Declined to participate
4 Were withdrawn by
investigator
27 Had a protocol withdrawal 
event and no open follow-up
164 Were at centers closed by 
data monitoring committee
168 Had other administrative
reasons
1086 Were alive at end of trial
6 Were lost to follow-up
Event for which data were censored
215 Died during double-blind
325 Declined to participate
10 Were withdrawn by
investigator
137 Had a protocol withdrawal 
event and no open follow-up
166 Were at centers closed by 
data monitoring committee
171 Had other administrative
reasons
866 Were alive at end of trial
10 Were lost to follow-up
Event for which data were censored
170 Died during double-blind
327 Declined to participate
11 Were withdrawn by
investigator
70 Had a protocol withdrawal 
event and no open follow-up
164 Were at centers closed by 
data monitoring committee
168 Had other administrative
reasons
1006 Were alive at end of trial
6 Were lost to follow-up
11 Were withdrawn for the
per-protocol analysis
6 Underwent randomization
in error
4 Did not receive correct
treatment
1 Was randomized to wrong
stratum
1922 Were included
in the per-protocol
analysis
(4025 total patient-yr)
1900 Were included
in the per-protocol
analysis
(3672 total patient-yr)
Figure 1. Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial.
Of the 461 patients who did not meet the protocol criteria, 229 did not meet the criteria on the basis of blood pressure, 18 on the basis 
of age, 61 on the basis of serum potassium level, 20 on the basis of serum creatinine level, 26 because they were receiving other antihy-
pertensive treatment, and 107 for other reasons. The other administrative reasons for the censoring of data were death or retirement of 
a local investigator and change in national legislation as to where patients in clinical trials could be seen.
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ern Europe (2144), China (1526), Australasia (19), 
and Tunisia (70). The two study groups were well 
balanced at baseline (Table 1). The age range at 
entry was 80 to 105 years, with 73.0% of patients 
80 to 84 years of age, 22.4% of patients 85 to 89 
years of age, and 4.6% of patients 90 years of age 
or older (interquartile range, 81.2 to 85.3). More 
than 90% of patients were known to be hyper-
tensive, of whom approximately one third had 
not been previously treated. A history of cardio-
vascular disease was reported in 11.8%, and dia-
betes was reported in 6.9%.
The median duration of follow up was 1.8 years 
(mean, 2.1; range, 0 to 6.5). The number of pa-
tient-years of follow-up was 3964 in the placebo 
group and 4159 in the active-treatment group. At 
the end of the trial, vital status was unknown in 
17 patients, 1882 patients were still undergoing 
double-blind follow-up, and 220 patients were un-
dergoing open follow-up.
According to the intention-to-treat analysis, at 
2 years, as compared with baseline, the systolic 
and diastolic blood pressure values obtained while 
the patient was seated had fallen by a mean (±SD) 
of 14.5±18.5 mm Hg and 6.8±10.5 mm Hg, re-
spectively, in the placebo group and by 29.5±15.4 
mm Hg and 12.9±9.5 mm Hg, respectively, in the 
active-treatment group. At 2 years, the mean sys-
tolic and diastolic blood pressure values obtained 
while the patient was standing had decreased by 
Table 1. Baseline Characteristics of the Patients.*
Characteristic Active Treatment (N = 1933) Placebo (N = 1912)
Age — yr 83.6±3.2 83.5±3.1
Female sex — no. (%) 1174 (60.7) 1152 (60.3)
Blood pressure — mm Hg
While sitting 173.0±8.4/90.8±8.5 173.0±8.6/90.8±8.5
While standing 168.0±11.0/88.7±9.3 167.9±11.1/88.6±9.3
Orthostatic hypotension — no. (%)† 152 (7.9) 169 (8.8)
Isolated systolic hypertension — no. (%) 625 (32.3) 623 (32.6)
Heart rate — beats/min 74.5±9.1 74.5±9.3
Cardiovascular history
Cardiovascular disease — no. (%) 223 (11.5) 229 (12.0)
Hypertension — no. (%) 1737 (89.9) 1718 (89.9)
Antihypertensive treatment — no. (%) 1241 (64.2) 1245 (65.1)
Stroke — no. (%) 130 (6.7) 131 (6.9)
Myocardial infarction — no. (%) 59 (3.1) 62 (3.2)
Heart failure — no. (%) 56 (2.9) 55 (2.9)
Cardiovascular risk factors
Current smoker — no. (%) 123 (6.4) 127 (6.6)
Diabetes — no. (%)‡ 132 (6.8) 131 (6.9)
Total cholesterol — mmol/liter 5.3±1.1 5.3±1.1
High-density lipoprotein cholesterol — mmol/liter 1.35±0.38 1.35±0.37
Serum creatinine — μmol/liter 88.6±20.5 89.2±20.5
Uric acid — μmol/liter 280.4±79.3 279.0±81.3
Body-mass index§ 24.7±3.8 24.7±3.5
* Plus–minus values are means ±SD. To convert values for cholesterol to milligrams per deciliter, divide by 0.02586; to con-
vert values for uric acid to milligrams per deciliter, divide by 59.48; and to convert values for serum creatinine to milli-
grams per deciliter, divide by 88.4.
† Orthostatic hypotension is defined as a drop in systolic blood pressure of more than 20 mm Hg or a reduction in dia-
stolic blood pressure of more than 10 mm Hg while standing.
‡ Diabetes is defined as reported diabetes, the receipt of antidiabetes treatment, or a random blood glucose measurement 
of more than 11.1 mmol per liter (200 mg per deciliter).
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
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13.6±18.9 mm Hg and 7.0±10.9 mm Hg, respec-
tively, in the placebo group and by 28.3±16.5 
mm Hg and 12.4±10.3 mm Hg, respectively, in 
the active-treatment group. There was a differ-
ence of 15.0/6.1 mm Hg in blood pressure, mea-
sured while patients were seated, between the 
two groups at 2 years (Fig. 2). Also at 2 years, 
the target blood pressure was reached in 19.9% 
of patients in the placebo group and in 48.0% in 
the active-treatment group (P<0.001).
At 2 years, 25.8%, 23.9%, and 49.5% of patients 
in the active-treatment group were receiving inda-
pamide alone, indapamide and perindopril (2 mg), 
and indapamide and perindopril (4 mg), respec-
tively; 14.2%, 13.4%, and 71.8% of patients in the 
placebo group, respectively, were receiving the 
corresponding placebos. The final main intention-
to-treat analysis included an extra 724 patient-
years of follow-up, with an additional 13 strokes 
and 54 deaths. This final analysis confirmed the 
treatment benefit for the risk of death from any 
cause and yielded a nearly significant benefit for 
the risk of fatal or nonfatal stroke.
With regard to the primary end point (fatal or 
nonfatal stroke), 51 events occurred in the active-
treatment group as compared with 69 events in 
the placebo group, a reduction in the rate of stroke 
of 30% (95% CI, −1 to 51; P = 0.06) (Table 2 and 
Fig. 3). This is equivalent to 11 strokes (95% CI, 
0 to 21) being prevented because 1000 patients 
were treated for 2 years or 1 stroke being prevented 
because 94 patients were treated for 2 years. There 
were a total of 431 deaths during the trial, with 
an overall rate of death of 53.1 per 1000 patient-
years. There was a 21% reduction (95% CI, 4 to 35; 
P = 0.02) in the rate of death from any cause in 
the active group. The rate of fatal stroke was re-
duced by 39% (95% CI, 1 to 62; P = 0.05). The rate 
of death from cardiac causes was not significantly 
reduced in the active-treatment group. The rate 
of death from cardiovascular causes was reduced 
by 23% (95% CI, −1 to 40; P = 0.06). The rate of 
fatal or nonfatal heart failure was reduced by 64% 
(95% CI, 42 to 78; P<0.001), and the rate of any 
cardiovascular event (death from cardiovascular 
causes or stroke, myocardial infarction, or heart 
failure) was reduced by 34% (95% CI, 18 to 47; 
P<0.001).
The benefits of treatment began to be appar-
ent within the first year (Fig. 3). When adjusted 
according to sex, age, baseline systolic blood 
pressure while seated, and previous cardiovascu-
lar disease, the results did not materially change 
for the end points of fatal or nonfatal stroke, 
death from any cause, or death from cardiovas-
cular causes.
According to per-protocol analyses, in the ac-
tive-treatment group as compared with the pla-
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Figure 2. Mean Blood Pressure, Measured while Patients Were Seated, in the Intention-to-Treat Population,  
According to Study Group.
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cebo group, the rate of stroke was reduced by 34% 
(95% CI, 5 to 54; P = 0.03), the rate of any heart 
failure by 72% (95% CI, 52 to 83; P<0.001), and the 
rate of death from cardiovascular causes by 27% 
(95% CI, 3 to 45; P = 0.03). In addition, the rate of 
death from any cause was decreased by 28% (95% 
CI, 12 to 41; P = 0.001) and the rate of death from 
stroke by 45% (95% CI, 7 to 67; P = 0.02).
Among the patients followed for at least 2 years, 
there were no significant differences between the 
two groups with regard to changes from baseline 
in the serum potassium level (−0.02 mmol and 
0.03 mmol per liter in the active-treatment group 
and in the placebo group, respectively; P = 0.09), 
uric acid (11.6 μmol and 3.5 μmol per liter [0.2 
and 0.1 mg per deciliter], P = 0.07), glucose (0.16 
mmol and 0.11 mmol per liter [2.9 and 2.0 mg 
per deciliter], P = 0.56), or creatinine (3.4 μmol and 
2.3 μmol per liter [0.04 and 0.03 mg per deciliter], 
P = 0.30). The number of serious adverse events 
reported was 448 in the placebo group and 358 in 
the active-treatment group (P = 0.001). Only five of 
these events (three in the placebo group and two 
in the active-treatment group) were classified by 
the local investigator as possibly having been due 
to the trial medication.
Discussion
The results of HYVET indicate that antihyperten-
sive treatment based on indapamide (sustained 
release, 1.5 mg), with or without 2 to 4 mg of per-
indopril, significantly reduces the risks of death 
from stroke and death from any cause in very 
elderly patients. This finding for stroke is consis-
tent with that seen in the HYVET pilot study18 
and the Individual Data Analysis of Antihyper-
tensive Drug Intervention Trials (INDANA) group 
meta-analysis.17 The reduction in death from any 
cause is a new and unexpected result.
As compared with clinical trials involving 
other age groups,11,14-16 the ratio of fatal to non-
fatal events was higher in HYVET. Although the 
number of strokes reported in HYVET (120) was 
similar to that reported in the Systolic Hyperten-
sion in Europe (Syst-Eur)16 trial (128 strokes) and 
higher than the number reported in the Swedish 
Trial in Older Patients with Hypertension (STOP–
Hypertension, 82 strokes),14 in HYVET the pro-
portion of fatal strokes (57.5%) was higher than 
that in Syst-Eur (28.9%) or STOP (18.3%). This 
difference probably reflects the older age of the 
patients in HYVET and the higher rates of stroke 
Table 2. Main Fatal and Nonfatal End Points in the Intention-to-Treat Population.
End Point
Rate per 1000 Patient-Yr  
(No. of Events)
Unadjusted Hazard Ratio 
(95% CI) P Value
Active Placebo
no. (%)
Stroke
Fatal or nonfatal 12.4 (51) 17.7 (69) 0.70 (0.49–1.01) 0.06
Death from stroke 6.5 (27) 10.7 (42) 0.61 (0.38–0.99) 0.046
Death
From any cause 47.2 (196) 59.6 (235) 0.79 (0.65–0.95) 0.02
From noncardiovascular or un-
known causes
23.4 (97) 28.9 (114) 0.81 (0.62–1.06) 0.12
From cardiovascular cause 23.9 (99) 30.7 (121) 0.77 (0.60–1.01) 0.06
From cardiac cause* 6.0 (25) 8.4 (33) 0.71 (0.42–1.19) 0.19
From heart failure 1.5 (6) 3.0 (12) 0.48 (0.18–1.28) 0.14
Fatal or nonfatal
Any myocardial infarction 2.2 (9) 3.1 (12) 0.72 (0.30–1.70) 0.45
Any heart failure 5.3 (22) 14.8 (57) 0.36 (0.22–0.58) <0.001
Any cardiovascular event† 33.7 (138) 50.6 (193) 0.66 (0.53–0.82) <0.001
* Death from cardiac causes was defined as fatal myocardial infarction, fatal heart failure, and sudden death.
† Any cardiovascular event was defined as death from cardiovascular causes or stroke, myocardial infarction, or heart failure.
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Figure 3. Kaplan–Meier Estimates of the Rate of End Points, According to Study Group.
For the active-treatment group as compared with the placebo group, the unadjusted hazard ratios (95% CIs) were as follows: for fatal or 
nonfatal stroke, 0.70 (0.49 to 1.01) (Panel A); for death from any cause, 0.79 (0.65 to 0.95) (Panel B); for death from cardiovascular causes, 
0.77 (0.60 to 1.01) (Panel C); for death from stroke, 0.61 (0.38 to 0.99) (Panel D); and for heart failure, 0.36 (0.22 to 0.58) (Panel E).
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that occur with increasing age.1 Increasing age 
is a major predictor of death from stroke,21-25 
with rates as high as 52%21 in persons 80 years 
of age or older, consistent with our results. A linear 
association between blood pressure and stroke re-
duction has been clearly demonstrated, although 
it is attenuated by increasing age.25 The reduction 
in the risk of death from stroke with active treat-
ment was significant in both the intention-to-treat 
and the per-protocol analyses, as was the reduc-
tion in the risk of any stroke in the per-protocol 
analysis. This reduction is consistent with previ-
ous results in younger hypertensive patients and 
in reviews of data from the very elderly.
An unexpected finding of our trial is the re-
duction in the risk of death from any cause with 
active treatment, making HYVET one of the few 
individual studies of hypertension showing ben-
efits of blood-pressure reduction on mortality.14,26 
The results for death from any cause show a sig-
nificant benefit of treatment, at odds with the 
results of the INDANA meta-analysis, the largest 
analysis to date to focus on very elderly patients 
with hypertension, which included 1670 patients 
80 years of age or older recruited for interven-
tion trials.17 The INDANA meta-analysis includ-
ed trials with treatment regimens based on high 
doses of diuretics other than indapamide or on 
beta-blockers. Diuretics have not been shown to 
increase mortality among younger patients, but 
the very elderly may be more prone to metabolic 
disturbances from medications, particularly hy-
pokalemia, which can predispose patients to ar-
rhythmias and possibly sudden death. Beta-block-
ers appear to be less effective than newer agents 
in the treatment of hypertension.27 Given the 
known changes in serum potassium level that 
can occur with a thiazide-like antihypertensive 
agent or angiotensin-converting–enzyme (ACE) in-
hibitor on its own, in combination, they are likely 
to have a neutral effect. This was evidenced by 
the similar serum potassium levels in the two 
groups, with 73.4% of patients in the active-treat-
ment group receiving both indapamide and per-
indopril at 2 years. Indapamide (sustained release) 
has also been shown to have a neutral effect on 
blood glucose and lipids,28 and the combination 
of indapamide and perindopril has also been 
shown to confer a benefit with regard to stroke.29
As in most trials, the patients in HYVET were 
generally healthier than those in the general popu-
lation, as evidenced by the low overall rates of 
stroke and death from any cause and the low 
prevalence of previous cardiovascular disease at 
baseline. It is possible that the numbers of pa-
tients needed to be treated is an overestimate, 
given the low rate of stroke, though a number 
needed to treat of 94 is acceptable in the context 
of prevention. A number needed to treat of 40 to 
prevent one death during a 2-year period is more 
impressive, supporting the effectiveness of the 
intervention used. However, it would be prema-
ture to extrapolate the results from HYVET to pa-
tients in this age group who are more frail.
The large reduction in the risk of heart failure 
in HYVET appears to be important. Heart failure 
is common in people older than 70 years of age, 
and hypertension is a major risk factor for heart 
failure.30 The combination of a diuretic and an 
ACE inhibitor is likely to confer a benefit. In the 
Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT; ClinicalTrials.
gov number, NCT00000542), the lowest rates of 
hospitalization and fatal heart failure were found 
for the groups receiving a diuretic or ACE inhibi-
tor, with a greater (albeit not significantly greater) 
reduction in the diuretic group.31
A challenge and possible limitation in per-
forming our study of the very elderly was the col-
lection of adequate information to validate the 
end-point data, especially for patients who died 
at home without receiving any direct medical 
intervention. The end-point committee required 
evidence to support a diagnosis of a stroke, and 
this evidence was not always available. Rapid and 
unexpected deaths were designated as deaths 
from cardiovascular causes by the committee. In 
the very elderly, it is difficult to establish the 
exact cause of death, since patients are often not 
monitored during the last hours of life and au-
topsies are rarely performed. Given these diffi-
culties, the reduction of the risk of death from 
any cause in the active-treatment group clearly 
indicates the overall advantage of active treat-
ment in HYVET.
In HYVET, we evaluated the benefit of treat-
ing patients who had a sustained systolic blood 
pressure of 160 mm Hg or higher. The fall in 
blood pressure in the active-treatment group was 
consistent with results for indapamide-based 
strategies in other studies.32,33 The results sup-
port a target blood pressure of 150/80 mm Hg in 
patients receiving treatment, since that target 
was reached in nearly 50% of such patients in 
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HYVET after 2 years. Whether further reduction 
is beneficial still needs to be established.
Elevated blood pressure is common in persons 
80 years of age or older,34 a group constituting 
the fastest-growing segment of the general popu-
lation.35 HYVET provides unique evidence that 
hypertension treatment based on indapamide (sus-
tained release), with or without perindopril, in 
the very elderly, aimed to achieve a target blood 
pressure of 150/80 mm Hg, is beneficial and is 
associated with reduced risks of death from 
stroke, death from any cause, and heart failure.
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